Qin Li: Influence Statistics

Qin Li

Qin Li

Motac Neuroscience, M15 6WE, Manchester, UK | Motac Neuroscience Ltd, Manchester, United Kingdom | Institute of Laboratory Animal Sciences & China Academy of Medical Sciences, ...

Qin Li: Expert Impact

Concepts for which Qin Li has direct influence: Induced dyskinesia , Parkinsons disease , Animal dyskinesia , Basal ganglia , Parkinson disease , Spraguedawley receptors , Primate model .

Qin Li: KOL impact

Concepts related to the work of other authors for which for which Qin Li has influence: Parkinson disease , Basal ganglia , Spinal cord , Induced dyskinesia , Animal models , Dopamine receptors , Rat model .

KOL Resume for Qin Li

Year
2022

Motac Neuroscience, M15 6WE, Manchester, UK

2021

Motac Neuroscience Ltd, Manchester, United Kingdom

Institute of Laboratory Animal Sciences & China Academy of Medical Sciences, Beijing, China

2020

Motac Neuroscience Ltd, Manchester, United Kingdom.

Institute of Lab Animal Sciences China Academy of Medical Sciences, Beijing, China.

2019

Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China

Motac Neuroscience, UK-M15 6WE, Manchester, United Kingdom

2018

Motac Neuroscience, UK‐M15 6WE, Manchester, United Kingdom

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing City, People's Republic of China

2017

Motac neuroscience Ltd, Manchester, UK

China Academy of Medical Sciences, Institute of Lab Animal Sciences Beijing China

2016

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences Beijing China

Motac Neuroscience Ltd Manchester UK

2015

Motac Neuroscience, Manchester M13 9XX, UK

Chinese Academy of Medical Science and Peking Union Medical College Institute of Laboratory Animal Sciences Beijing China

2014

China Academy of Medical Sciences, Institute of Laboratory Animal Sciences, Beijing, China

Motac neuroscience, Manchester, UK

2013

Motac France, Floirac, France

Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden

2012

Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, 100050 Beijing, China,

Motac Cognition Inc, Beijing, China

2011

4 Institute of Laboratory Animal Sciences, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China

2010

Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing 100050, China.

Department of Nuclear Medicine of Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

2009

Motac Collaborative Laboratory, Institute of Laboratory Animal Science, CAMS&PUMC, Beijing, People's Republic of China

2008

Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, 100021 Beijing, China

2007

ILAS, China Academy of Medical Sciences, Beijing, China

2006

Lab Animal Research Center, China Agricultural University, Beijing, China

Prominent publications by Qin Li

KOL-Index: 14441 . Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa therapy for Parkinson's disease. Although changes affecting D(1) and D(2) dopamine receptors have been studied in association with this condition, no causal relationship has yet been established. Taking advantage of a monkey brain bank constituted to study levodopa-induced dyskinesia, we report changes ...
Known for D1 Dopamine | Induced Dyskinesia | Dyskinetic Animals | Cyclin Dependent
KOL-Index: 13956 . Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease patients and represents a major limitation for the pharmacological management of the motor symptoms in advanced disease stages. We have recently demonstrated that dopamine released from serotonin neurons is responsible for l-DOPA-induced dyskinesia in 6-hydroxydopamine (6-OHDA)-lesioned rats, ...
Known for Receptor Agonists | Induced Dyskinesia | Serotonin 5 | Dopa Treatment
KOL-Index: 12906 . Spinal cord injury disrupts the communication between the brain and the spinal circuits that orchestrate movement. To bypass the lesion, brain-computer interfaces have directly linked cortical activity to electrical stimulation of muscles, and have thus restored grasping abilities after hand paralysis. Theoretically, this strategy could also restore control over leg muscle activity for ...
Known for Spinal Cord Injury | Cord Stimulation | Motor Cortex | Macaca Mulatta
KOL-Index: 12862 . The serotonin (5-hydroxytryptamine [5HT]) system has recently emerged as an important player in the appearance of l-3,4-dihydroxyphenylalanine (levodopa [l-dopa])-induced dyskinesia in animal models of Parkinson's disease. In fact, dopamine released as a false transmitter from serotonin neurons appears to contribute to the pulsatile stimulation of dopamine receptors, leading to the ...
Known for Animal Models | Induced Dyskinesia | Serotonin Neurons | Antidyskinetic Amantadine
KOL-Index: 12498 . Dyskinesias represent a debilitating complication of levodopa therapy for Parkinson's disease (PD). While we recently demonstrated that levodopa-induced dyskinesia results from increased dopamine D(1) receptor-mediated transmission, we also questioned the possible role of subcellular localization of D(1) and D(2) receptors in mediating these effects as we previously showed that D(1) ...
Known for D1 Dopamine | Striatal Neurons | Receptor Trafficking | Parkinsonian Monkeys
KOL-Index: 10711 . BACKGROUND: In rodents, the development of dyskinesia produced by L-DOPA in the dopamine-depleted striatum occurs in response to increased dopamine D1 receptor-mediated activation of the cAMP - protein kinase A and of the Ras-extracellular signal-regulated kinase (ERK) signalling pathways. However, very little is known, in non-human primates, about the regulation of these signalling ...
Known for Protein Kinase | Extracellular Signal | Dyskinesia Erk | Camp Regulated
KOL-Index: 10679 . BACKGROUND: A role for enhanced opioid peptide transmission has been suggested in the genesis of levodopa-induced dyskinesia. However, basal ganglia nuclei other than the striatum have not been regarded as potential sources, and the opioid precursors have never been quantified simultaneously with the levels of opioid receptors at the peak of dyskinesia severity. METHODS: The levels of ...
Known for Subthalamic Nucleus | Induced Dyskinesia | Opioid Transmission | Basal Ganglia
KOL-Index: 10559 . BACKGROUND: ΔFosB is a surrogate marker of L-DOPA-induced dyskinesia (LID), the unavoidable disabling consequence of Parkinson's disease L-DOPA long-term treatment. However, the relationship between the electrical activity of FosB/ΔFosB-expressing neurons and LID manifestation is unknown. METHODS: We used the Daun02 prodrug-inactivation method associated with lentiviral expression of ...
Known for Induced Dyskinesia | Selective Inactivation | Expressing Neurons | Disease Dopa
KOL-Index: 10370 . Parkinson's disease is caused primarily by degeneration of brain dopaminergic neurons in the substantia nigra and the consequent deficit of dopamine in the striatum. Dopamine replacement therapy with the dopamine precursor l-dopa is the mainstay of current treatment. After several years, however, the patients develop l-dopa-induced dyskinesia, or abnormal involuntary movements, thought to ...
Known for Induced Dyskinesia | Dopamine Receptors | Parkinsons Disease | Parkinsonian Rats
KOL-Index: 10257 . The classic view of anatomofunctional organization of the basal ganglia is that striatopallidal neurons of the "indirect" pathway express D2 dopamine receptors and corelease enkephalin with GABA, whereas striatopallidal neurons of the "direct" pathway bear D1 dopamine receptors and corelease dynorphin and substance P with GABA. Although many studies have investigated the pathophysiology of ...
Known for Basal Ganglia | Medium Spiny Neurons | Dopamine Receptors | Nonhuman Primates
KOL-Index: 9642 . INTRODUCTION: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons as well as the presence of proteinaceous inclusions named Lewy bodies. α-synuclein (α-syn) is a major constituent of Lewy bodies, and the first disease-causing protein characterized in PD. Several α-syn-based animal models of PD have been developed to ...
Known for Α Syn | Nigrostriatal Neurodegeneration | Mice Rats | Lewy Bodies
KOL-Index: 9521 . In the present study we investigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogenesis of Parkinson's disease, also affects L-DOPA-induced dyskinesia. In striatal slices of naive rodents, N/OFQ (0.1-1 μm) prevented the increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the D1 receptor agonist ...
Known for Induced Dyskinesia | Receptor Agonist | Orphanin Fq | Synaptic Plasticity
KOL-Index: 9493 . BACKGROUND: Involuntary movements, or dyskinesia, represent a debilitating complication of dopamine replacement therapy for Parkinson disease (PD). The transcription factor DeltaFosB accumulates in the denervated striatum and dimerizes primarily with JunD upon repeated L-3,4-dihydroxyphenylalanine (L-DOPA) administration. Previous studies in rodents have shown that striatal DeltaFosB ...
Known for Parkinson Disease | Striatal Overexpression | Induced Dyskinesia | Primate Model
KOL-Index: 9489 . Amantadine, an N-methyl-D-aspartate glutamate receptor antagonist, is currently the only pharmacological treatment for levodopa-induced dyskinesia (LID) in Parkinson's disease (PD), but causes adverse effects on the central nervous system at therapeutic doses. Fenobam, a negative modulator of metabotropic glutamate receptor subtype 5, has recently been reported to attenuate LID in ...
Known for Amantadine Treatment | Combination Dyskinesia | Parkinsons Disease | Central Nervous
KOL-Index: 9220 . Dyskinesia represents a debilitating complication of L-3,4-dihydroxyphenylalanine (L-dopa) therapy for Parkinson's disease. Such motor manifestations are attributed to pathological activity in the motor parts of basal ganglia. However, because consistent funneling of information takes place between the sensorimotor, limbic, and associative basal ganglia domains, we hypothesized that ...
Known for Basal Ganglia | Induced Dyskinesia | Motor Manifestations | Debilitating Complication

Key People For Induced Dyskinesia

Top KOLs in the world
#1
Maria Angela Cenci
rat model induced dyskinesia parkinsons disease
#2
Erwan Bezard
parkinsons disease basal ganglia induced dyskinesia
#3
Jonathan Michael Brotchie
parkinsons disease basal ganglia globus pallidus
#4
Anders Björklund Björklund
parkinsons disease dopamine neurons substantia nigra
#5
Martin Lundblad
rat model dopamine release induced dyskinesia
#6
Manolo Carta
induced dyskinesia animal models serotonin neurons

Motac Neuroscience, M15 6WE, Manchester, UK | Motac Neuroscience Ltd, Manchester, United Kingdom | Institute of Laboratory Animal Sciences & China Academy of Medical Sciences, Beijing, China | Motac Neuroscience, Manchester, UK | Institute of Laborat